CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- Open-market buys, last 90 days
- $252,875
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$252,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-04 | Freve Jonathan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2023-01-04 | Lindmark Bertil Chief Medical Officer | Grant or award · Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2022-06-14 | Munshi Amit Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2022-06-14 | Shapiro David Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2022-06-14 | Prener Anne Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2022-06-14 | Khuong Chau Quang Director | Grant or award · /s/ Jonathan Freve, attorney-in-fact | +18,000 | 18,000 | ||
| 2022-06-14 | GOLDFISCHER CARL Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2022-06-14 | Dallas Jayson Donald Alexander Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2022-03-22 | Lindmark Bertil Chief Medical Officer | Purchase | +14,604 | $2.16 | $32K | 16,604 |
| 2022-03-22 | Schambye Hans T. Chief Executive Officer | Purchase | +5,000 | $2.15 | $11K | 52,428 |
| 2022-02-15 | Oestreich Stephanie Chief Business Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2022-01-04 | Schambye Hans T. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +287,500 | 287,500 | ||
| 2022-01-04 | Lindmark Bertil Chief Medical Officer | Grant or award · Stock Option (right to buy) | +118,750 | 118,750 | ||
| 2022-01-04 | Winslow Garrett General Counsel | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2022-01-04 | Pedersen Anders Chief Operating Officer | Grant or award · Stock Option (right to buy) | +118,750 | 118,750 | ||
| 2022-01-04 | Freve Jonathan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +118,750 | 118,750 | ||
| 2021-12-03 | Winslow Garrett General Counsel | Purchase | +2,000 | $2.48 | $5K | 4,000 |
| 2021-12-03 | Freve Jonathan Chief Financial Officer | Purchase | +4,000 | $2.49 | $10K | 12,000 |
| 2021-11-17 | Khuong Chau Quang Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2021-11-17 | GOLDFISCHER CARL Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 |
Page 7 of 12 · 227 trades